A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

Ketamine has been used as an anesthetic before surgeries for decades, but it can also be an option for those struggling with ...

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...

Ketamine therapy is now a mainstream prescription for treatment-resistant depression. Read more at straitstimes.com.

The FDA approved Johnson & Johnson's Spravato, a ketamine-based nasal spray, to treat adults with major depressive disorder who have not responded to at least two oral antidepressants. This approval ...